BioSpace News Archive

Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that the Company will participate in the following upcoming investor conferences: Citi’s 15th Annual BioPharma Virtual Conference: Frank DeRosa, Chief Technology Officer, will participate in a panel discussing COVID-

Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced the appointment of Robert Ross , M.D., to its Board of Directors. Dr. Ross currently s

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming virtual investor conferences: Baird 2020 Virtual Global Healthcare Confere

Successful Pregnancy Outcomes Rose to 64% Following Treatment in BCL6-Positive Patients on Next IVF Transfer; Previous Published Success Rates on Follow-On Transfers Without Treatment Only 12%

Fulgent Genetics, Inc., a technology company providing comprehensive testing solutions through its scalable technology platform, announced that beginning September 28th, all patients tested for COVID-19 by Fulgent Genetics will also receive results for Influenzas A and B.

Nemaura Medical, Inc. announced that its CEO Dr. Faz Chowdhury will be presenting at the LD 500 investor conference on Thursday, September 3, 2020 at 10:20 a.m. ET.

Centogene N.V., a commercial-stage diagnostics and genetic research company, announced that its scientific publication ‘Successful application of genome sequencing in a diagnostic setting: 1,007 index cases from a clinically heterogeneous cohort’ has appeared in the European Journal of Human Genetics - one of the world’s leading medical genetic journals.

Avivagen Inc., a world leader in natural alternatives to antibiotics with its OxC-beta™ technology, has announced its unaudited financial results for the third quarter of 2020.

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the forthcoming presentation of efficacy and safety results from the pivotal MOXIe Part 2 study, a randomized, double-blind, placebo-controlled trial of omaveloxolone in Friedreich’s ataxia.

Amicus Therapeutics announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in September: